Letrozol Hikma

Letrozole, the active ingredient in Letrozol Hikma, is an aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozol Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Letrozol Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Letrozole is used in endocrine‑related oncology, targeting estrogen‑driven breast cancer pathways.

- Hormone receptor‑positive breast cancer: Reduces tumour growth by lowering estrogen levels in postmenopausal women. - Adjuvant therapy after surgery: Helps prevent cancer recurrence following tumor removal. - Metastatic breast cancer: Provides disease control when cancer has spread beyond the breast. - Neoadjuvant therapy: Shrinks tumours before surgical intervention. - Hormone‑sensitive ovarian ​  ​  ​  ​  ​  ​  ​  ​  ​  ​

Letrozole     …  

Common  

  ullet   \\  ...

...